Terminated PHASE3 INTERVENTIONAL NCT00134953

Efficacy and Safety of Rivastigmine in Patients With Mild Cognitive Impairment

Sponsor: Novartis

Updated 6 times since 2017 Last updated: Dec 14, 2007 Started: Jan 31, 2003 Completion: May 31, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

The Principal Investigator left the clinic and there was no one who could take over this study.

Other terminated trials from Novartis

See all terminations from Novartis

A PHASE3 clinical study on Cognitive Symptoms, this trial is terminated or withdrawn. The trial is conducted by Novartis and has accumulated 6 data snapshots since 2003. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE3
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE3
Aug 2017 — Jun 2018 [monthly]

Terminated PHASE3

▶ Show 1 earlier version

Jan 2017 — Aug 2017 [monthly]

Terminated PHASE3

First recorded

Jan 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis

Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.